From here.
Three months after rumors surfaced that Bristol-Myers Squibb was pursuing Amylin Pharmaceuticals, a deal has been struck. The big drugmaker has agreed to pay $5.3 billion – and assume $1.7 billion in debt – in hopes of strengthening its position in the competitive diabetes market. And in connection with the deal, which effectively amounts to $7 billion, AstraZeneca will pay $3.4 billion to Bristol-Myers to expand their existing diabetes partnership.
Well, I like this numbers... However it is very hard to imagine how anybody could spend them...
No comments:
Post a Comment